ABVX
Abivax S.A.
NASDAQ · Healthcare · Biotechnology · FR
$114.71
+0.59%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- -73.5%
- EPS
- +16.6%
- Free cash flow
- -11.1%
- Operating cash flow
- -14.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +52.3%
- EPS
- +22.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- -84.8%
- EBIT
- -42.2%
- Net income
- -90.7%
- EPS
- -66.1%
- Free cash flow
- -0.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025